ArticleEuropean heart journal. Quality of care & clinical outcomes2026
Determinants of symptom relief and quality of life improvement after atrial fibrillation ablation.
Article in European heart journal. Quality of care & clinical outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe primary goal of atrial fibrillation (AF) ablation is to improve AF-related symptoms and quality of life. Previous studies have observed a discrepancy between objective recurrence of AF after ablation and patient-perceived change of symptoms. Although predictors of freedom of AF recurrence after AF ablation have been widely studied, factors associated with symptom relief and quality of life improvement remain underexplored. The present study aimed to investigate determinants of symptom reduction and improvement in quality of life after AF ablation. METHODS AND
resultsA total of 382 AF patients (68% paroxysmal AF, 67% male, mean age 63 ± 9 years) undergoing AF ablation were included. Patient-reported outcomes were assessed using the Toronto Atrial Fibrillation Severity Scale (AFSS) and 36-Item Short-Form Health Survey (SF-36) score. Patients completed both the AFSS and SF-36 score pre-ablation, and post-ablation at 4 months and 1 year follow-up. Atrial tachyarrhythmia recurrence was documented in 139 patients (36%) at 1 year follow-up. AF symptom severity, patient-perceived AF burden and quality of life improved from baseline to 1 year follow-up, particularly in patients without atrial tachyarrhythmia recurrence. Greater baseline AFSS-derived symptom severity and patient-perceived AF burden were associated with a greater improvement of AF symptom severity and patient-perceived AF burden after ablation.
conclusionThis study shows that patients with lower quality of life and greater AF symptom severity and patient-perceived AF burden benefit most from AF ablation, suggesting that more emphasis should be put on the burden of AF symptoms in clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.